Nrx pharmaceuticals (nasdaq: nrxp) demonstrates compliance with nasdaq mvls standard

Company to present full compliance plan, based on achieving clinical milestones, to nasdaq on january 4, 2024 radnor, pa., jan. 2, 2024 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals", the "company"), a clinical-stage biopharmaceutical company today announced an update on plans to achieve compliance with nasdaq market requirements related to minimum bid price and total market value of listed securities (mvls).
NRXP Ratings Summary
NRXP Quant Ranking